U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H34O11
Molecular Weight 534.5523
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHILLYRIN

SMILES

COC1=CC=C(C=C1OC)[C@@H]2OC[C@H]3[C@@H]2CO[C@@H]3C4=CC=C(O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(OC)=C4

InChI

InChIKey=KFFCKOBAHMGTMW-LGQRSHAYSA-N
InChI=1S/C27H34O11/c1-32-17-6-4-13(8-19(17)33-2)25-15-11-36-26(16(15)12-35-25)14-5-7-18(20(9-14)34-3)37-27-24(31)23(30)22(29)21(10-28)38-27/h4-9,15-16,21-31H,10-12H2,1-3H3/t15-,16-,21+,22+,23-,24+,25-,26+,27+/m0/s1

HIDE SMILES / InChI

Molecular Formula C27H34O11
Molecular Weight 534.5523
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27323762 https://www.ncbi.nlm.nih.gov/pubmed/24995500

Phillyrin, an active ingredient found in many medicinal plants and certain functional foods, elicits anti-obesity and anti-inflammatory properties in vivo. Phillyrin is one of the main chemical constituents of Forsythia suspensa (Thunb.), which has shown to be an important traditional Chinese medicine. Phillyrin, has being shown to possess various bioactivities, including anti-inflammatory, anti-oxidant, and antiviral activities. It has being reported that Phillyrin attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1/AMP-activated protein kinase-dependent signalling.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Phillyrin, a natural lignan, attenuates tumor necrosis factor α-mediated insulin resistance and lipolytic acceleration in 3T3-L1 adipocytes.
2014-07
Phillyrin attenuates LPS-induced pulmonary inflammation via suppression of MAPK and NF-κB activation in acute lung injury mice.
2013-10
Patents

Patents

Sample Use Guides

i.p., 10 or 20 mg/kg/day for 3 days
Route of Administration: Intraperitoneal
Phillyrin inhibits release of the cyclo-oxygenase metabolites prostaglandin E2 (IC50 value 45.6 uM) and to a lesser extent reducing thromboxane B2 levels (IC50 value 168 uM) in human platelets
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:19:30 GMT 2025
Edited
by admin
on Mon Mar 31 22:19:30 GMT 2025
Record UNII
VE9P4964MG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FORSYTHIN
Preferred Name English
PHILLYRIN
MI  
Common Name English
PHYLLYRIN
Common Name English
4-((1S,3AR,4R,6AR))-4-(4-(3,4-DIMETHOXYPHENYL)TETRAHYDRO-1H,3H-FURO(3,4-C)FURAN-1-YL)-2-METHOXYPHENYL-.BETA.-D-GLUCOPYRANOSIDE
Systematic Name English
.BETA.-D-GLUCOPYRANOSIDE, 4-((1S,3AR,4R,6AR)-4-(3,4-DIMETHOXYPHENYL)TETRAHYDRO-1H,3H-FURO(3,4-C)FURAN-1-YL)-2-METHOXYPHENYL
Systematic Name English
PHILLYROSIDE, (+)-
Common Name English
PHILLYRIN [MI]
Common Name English
Code System Code Type Description
MERCK INDEX
m8704
Created by admin on Mon Mar 31 22:19:30 GMT 2025 , Edited by admin on Mon Mar 31 22:19:30 GMT 2025
PRIMARY Merck Index
WIKIPEDIA
Phillyrin
Created by admin on Mon Mar 31 22:19:30 GMT 2025 , Edited by admin on Mon Mar 31 22:19:30 GMT 2025
PRIMARY
CAS
487-41-2
Created by admin on Mon Mar 31 22:19:30 GMT 2025 , Edited by admin on Mon Mar 31 22:19:30 GMT 2025
PRIMARY
EPA CompTox
DTXSID40197589
Created by admin on Mon Mar 31 22:19:30 GMT 2025 , Edited by admin on Mon Mar 31 22:19:30 GMT 2025
PRIMARY
FDA UNII
VE9P4964MG
Created by admin on Mon Mar 31 22:19:30 GMT 2025 , Edited by admin on Mon Mar 31 22:19:30 GMT 2025
PRIMARY
SMS_ID
300000044122
Created by admin on Mon Mar 31 22:19:30 GMT 2025 , Edited by admin on Mon Mar 31 22:19:30 GMT 2025
PRIMARY
PUBCHEM
101712
Created by admin on Mon Mar 31 22:19:30 GMT 2025 , Edited by admin on Mon Mar 31 22:19:30 GMT 2025
PRIMARY